Early data on the transmission of SARS-CoV-2 in Wuhan cancer patients have been published

Patients with non-low-risk breast cancer in situ may experience poorer functional and cosmetic outcomes with use of tumour bed radiotherapy boost during breast-conserving therapy

Bemarituzumab may be a new option for the treatment of fibroblast growth factor receptor (FGFR) 2b-overexpressing advanced gastric and gastro-oesophageal junction adenocarcinoma

Pemigatinib shows second-line activity against locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 gene alterations

Sequencing has identified germline pathogenic or likely pathogenic variants in more than a quarter of osteosarcoma patients tested

Imaging-based chemoradiotherapy may be able to reduce target volume size without adversely affecting control of locally advanced non-small-cell lung cancer

Tumour deposits might help guide prognosis and duration of adjuvant therapy in stage III colorectal cancer

Adding pertuzumab to first-line trastuzumab and docetaxel significantly increases overall survival for HER2-positive metastatic breast cancer patients over 8 years of follow-up